To evaluate the effectiveness of bisphosphonate therapy in reducing fracture risk among young adults, specifically premenopausal women, with a history of osteoporotic fractures.
Key Findings:
Ibandronate users showed significant reductions in both major osteoporotic (HR 0.376, 95% CI 0.164-0.861) and nonvertebral fractures (HR 0.214, 95% CI 0.052-0.877), highlighting the effectiveness of this specific treatment.
Interpretation:
Bisphosphonate therapy significantly reduces fracture risk in premenopausal women with previous osteoporotic fractures, particularly with higher cumulative doses.
Limitations:
The study is retrospective and may be subject to biases inherent in observational studies.
The cohort was limited to premenopausal women, which may not generalize to other populations.
Potential lack of long-term follow-up data may affect the assessment of sustained efficacy.
Conclusion:
The findings support considering bisphosphonates as a treatment option for premenopausal women at high risk of fractures, while also highlighting the need for further research on their efficacy in young adults.
